NYSE:CTLTCatalent Stock Price, Forecast & News

Catalent's stock was trading at $46.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CTLT stock has increased by 68.8% and is now trading at $77.73. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catalent.

Catalent is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020. View our earnings forecast for Catalent.

Catalent Inc (NYSE:CTLT) released its quarterly earnings results on Tuesday, May, 5th. The company reported $0.50 EPS for the quarter, topping the Zacks' consensus estimate of $0.45 by $0.05. The company earned $760.60 million during the quarter, compared to the consensus estimate of $696.10 million. Catalent had a return on equity of 14.58% and a net margin of 4.79%. The firm's quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.49 earnings per share. View Catalent's earnings history.

Catalent issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, May, 5th. The company provided earnings per share guidance of 1.79-1.93 for the period, compared to the Thomson Reuters consensus estimate of $1.78. The company issued revenue guidance of $2.87-2.95 billion, compared to the consensus revenue estimate of $2.83 billion.

7 Wall Street analysts have issued twelve-month target prices for Catalent's shares. Their forecasts range from $62.00 to $77.00. On average, they expect Catalent's share price to reach $70.00 in the next year. This suggests that the stock has a possible downside of 9.9%. View analysts' price targets for Catalent.

Headlines about CTLT stock have trended positive on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Catalent earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutCatalent.

Some companies that are related to Catalent include ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), UCB (UCBJF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Beigene (BGNE) and Sarepta Therapeutics (SRPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Alibaba Group (BABA), Energy Transfer LP Unit (ET), Pfizer (PFE), AT&T (T), Thermo Fisher Scientific (TMO), CVS Health (CVS), AbbVie (ABBV), Johnson & Johnson (JNJ) and Amgen (AMGN).

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (10.18%), BlackRock Inc. (10.43%), JPMorgan Chase & Co. (4.59%), Champlain Investment Partners LLC (3.17%), Franklin Resources Inc. (2.55%) and State Street Corp (2.43%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Michael J Grippo, Peter L Buzy, Ricardo Pravda, Steven L Fasman and William Downie. View institutional ownership trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Janus Henderson Group PLC, Wellington Management Group LLP, Schroder Investment Management Group, Principal Financial Group Inc., Bernzott Capital Advisors, Nuveen Asset Management LLC, and GW&K Investment Management LLC. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Michael J Grippo, Ricardo Pravda, and Steven L Fasman. View insider buying and selling activity for Catalent.

CTLT stock was purchased by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, JPMorgan Chase & Co., BlackRock Inc., Viking Global Investors LP, The Manufacturers Life Insurance Company , Invesco Ltd., Clearbridge Investments LLC, and Federated Hermes Inc.. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch, and Peter L Buzy. View insider buying and selling activity for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $77.73.

Catalent has a market capitalization of $12.04 billion and generates $2.52 billion in revenue each year. The company earns $137.40 million in net income (profit) each year or $1.62 on an earnings per share basis. Catalent employs 12,300 workers across the globe.

The official website for Catalent is www.catalent.com.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]